Compare AbCellera Biologics Inc (ABCL) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs ProShares UltraPro S&P500 — how do they compare? AbCellera Biologics Inc trades at $8.94 (market cap $2.85B), while ProShares UltraPro S&P500 trades at $154.15. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, AbCellera Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | UPRO | |
|---|---|---|
Market Cap | $2.85B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $9.76 | $155.10 |
52-Week Low | $2.78 | $89.29 |
Enterprise Value | $2.45B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
UPRO trades at $155.10, up 1.72% on the day, with a bullish technical signal from moving averages and a neutral oscillator reading. The stock faces resistance near $156 and support at $154, while the RSI indicates potential overbought conditions. Recent news highlights S&P 500 strength, with JPMorgan raising its 2026 target to 8,000, driven by AI-driven earnings growth and robust corporate performance.
The outlook remains positive amid strong market momentum, but risks include overvaluation concerns and sensitivity to economic data. Upside potential hinges on sustained earnings growth, while pullbacks may occur if breadth weakens or inflation fears resurface.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
